Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

522.41 -7.18 (-1.35%)
Streaming Delayed Price Updated: 3:23 PM EDT, Jul 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth Meets a Technical Setup for a Potential Breakout ↗
Via Chartmill
News headline image
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗
Are there significant gains ahead for one (or both) of these innovative biotechs? 
Via The Motley Fool
Which S&P500 stocks are moving on Tuesday? ↗
Via Chartmill
News headline image
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? ↗
The biotech's innovative platform could pay off. 
Via The Motley Fool
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Fits the Affordable Growth Profile With Strong Earnings and Reasonable Valuation ↗
Via Chartmill
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 Estimates as New Drug Launches Drive Diversification ↗
Via Chartmill
Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth Stock with Promising Technical Setup ↗
Via Chartmill
News headline image
Vertex to Participate in Upcoming May Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call
Vertex Pharmaceuticals' first quarter results reflected balanced growth across its cystic fibrosis franchise and newly launched therapies, with management hi... 
Via StockStory
Topics Earnings
News headline image
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Is This Millionaire-Maker Biotech Stock a Buy Right Now? ↗
The market wasn't impressed by its latest quarterly update. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Vertex (VRTX) Q1 2026 Earnings Call Transcript ↗
Vertex (VRTX) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Vertex Pharmaceuticals Reports Mixed Q1 Results ↗
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports financial results for the first quarter after the market close on Monday. 
Via Benzinga
News headline image
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 CY2026 Sales Expectations
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 7.8% year on year to $2.99 billion. ... 
Via StockStory
News headline image
Vertex Reports First Quarter 2026 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex (VRTX) Q2 2025 Earnings Call Transcript ↗
Vertex (VRTX) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Vertex Pharmaceuticals (VRTX) Q1 Earnings: What To Expect
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what investors should know. Vertex Pharmace... 
Via StockStory
News headline image
Got $1,000? Which of These Beaten-Down Healthcare Stocks Is Worth Buying? ↗
These longtime market beaters may not have peaked yet. 
Via The Motley Fool
Topics World Trade
News headline image
Set It and Forget It: 3 Monster Stocks Worth Holding Through Whatever Comes Next ↗
They may suffer the occasional knee-jerk setback. By and large, though, investors understand these companies are capable of standing up to almost any challenge. 
Via The Motley Fool
Topics Credit Cards Economy
News headline image
Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering ↗
These companies are leaders in their fields. 
Via The Motley Fool
News headline image
What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. ↗
The biotech's candidate may treat a great number of illnesses that have one thing in common. 
Via The Motley Fool
News headline image
Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead? ↗
This particular player has seen its yield rise in recent years. 
Via The Motley Fool
News headline image
3 Growth Stocks That Could Generate 10X Returns ↗
These stocks come with risk, but they also have some exciting long-term growth opportunities. 
Via The Motley Fool
Topics Cannabis Law Enforcement
News headline image
3 of Wall Street’s Favorite Stocks Worth Your Attention
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
3 Market-Beating Stocks to Consider Right Now
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ... 
Via StockStory
Topics Energy
News headline image
3 Healthcare Stocks With the Most Durable Competitive Moats ↗
These companies offer a clear path to sustained earnings growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? ↗
We'll know more about the company's medium-term prospects by the end of the year. 
Via The Motley Fool
News headline image
2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term ↗
Vertex Pharmaceuticals has given Mirum Pharmaceuticals the blueprint for success in rare diseases. 
Via The Motley Fool
News headline image
Is Vertex Pharmaceuticals' Empire in Trouble? ↗
It might not be too late to invest in this company. 
Via The Motley Fool
News headline image
1 S&P 500 Stock on Our Watchlist and 2 Facing Challenges
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.